KALA News and Press, Kala Pharmaceuticals Inc. From 11/08/22

-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GL...

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare disea...

Kala Pharmaceuticals ( NASDAQ: KALA ) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s ( KALA ) issued and outstanding c...

ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare disea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another look at the biggest pre-market stock movers as we check out what’s happening Tuesday morning! Moving stocks this morning are heavy trading, acqui...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharrmaceuticals Investor Presentation - Slideshow

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present a...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another breakdown of the biggest pre-market stock movers and the news moving them on Wednesday! We’ve got a SPAC merger, special shareholder meetings, st...

Kala Pharmaceuticals, Inc. (KALA) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Hannah Deresiewicz – Stern Investor Relations Mark Iwicki – Chief Executive Officer Kim Brazzell – Head-R&D and Chief Medic...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharmaceuticals (KALA) Investor Presentation (Slideshow)